Skip to main content
. 2021 Jun 8;6(11):e144920. doi: 10.1172/jci.insight.144920

Figure 4. eFT508 treatment causes reduced tumor size and improved survival in phospho-eIF4E high bladder cancer PDX model.

Figure 4

(A–C) Growth curve (Inset: representative phospho-eIF4E staining in the TM01029 PDX) (A), Kaplan-Meier curve (B), and representative IHC and bar graph of cleaved caspase 3 (CC3) (C) of the TM01029 (high phospho-eIF4E) PDX model treated daily with eFT508 10 mg/kg orally (n = 10 [control]; n = 13 [eFT50])). (D–F) Growth curve (Inset: representative phospho-eIF4E staining in the CoCaB1 PDX) (D Kaplan-Meier curve (E), and representative IHC and bar graph of cleaved caspase 3 (CC3) (F) of the CoCaB1 (low phospho-eIF4E) PDX model treated daily with eFT508 10 mg/kg orally (n = 9 [control]; n = 8 [eFT508]). (G) Phospho-eIF4E S209 levels in primary bladder cancer specimens compared with matched normal tissues (n = 25 patients, P < 0.05, t test). (H) Phospho-eIF4E S209 levels across 53 primary bladder cancer specimens demonstrating that 37% of patients express high levels of phosphorylated eIF4E. Scale bars: 1 mm. Data are presented as mean ± SEM.